A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma - Trial NCT05929612
Access comprehensive clinical trial information for NCT05929612 through Pure Global AI's free database. This Phase 2 trial is sponsored by M.D. Anderson Cancer Center and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
M.D. Anderson Cancer Center
Timeline & Enrollment
Phase 2
Jul 28, 2023
Dec 31, 2027
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Summary
To learn if response-adapted, ultra-low dose radiation therapy can help to control MZL. This
 means participates first receive lower does of radiation therapy and then, based on how the
 disease responds, may receive higher doses after that.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05929612
Non-Device Trial